Xenon Pharmaceuticals is a biotechnology company focused on developing innovative therapies for neurological disorders. Its core products include treatments for conditions such as epilepsy and pain management. The company primarily generates revenue through the development and commercialization of its drug candidates, which are in various stages of clinical trials. Xenon aims to address unmet medical needs in the healthcare sector, leveraging its proprietary drug discovery platform.
The investment profile of Xenon Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and potential for future revenue generation. The lack of dividends and the current negative earnings per share suggest a higher risk profile, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-29 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-08-27 | Sell | Hold | Strong momentum, but negative EPS raises concerns. |
| 2026-08-21 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-08-13 | Sell | Hold | Strong momentum but negative fundamentals raise concerns. |
| 2026-08-02 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-07-18 | Buy | Hold | Strong momentum but negative earnings raise concerns. |
| 2026-07-10 | Hold | Buy | Strong momentum and positive price performance indicate growth potential. |
| 2026-06-23 | Sell | Hold | Weak fundamentals with mixed momentum signals. |
| 2026-06-03 | Hold | Sell | Weak fundamentals and negative momentum raise significant risk. |
| 2026-05-20 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-05-08 | — | Sell | Weak fundamentals and negative momentum raise uncertainty. |
| 2026-05-08 | Hold | Hold | Компания показывает сильный рост за последние 60 и 120 дней, но недавние колебания цен и отрицательный EPS указывают на неопределенность в краткосрочной перспективе. |
| 2026-03-10 | — | Hold | Компания демонстрирует значительный рост цен за последние месяцы, что указывает на сильный интерес инвесторов. Однако отсутствие данных по EPS и выручке может свидетельствовать о высоком риске. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-28 | Jefferies | Target Lowered | — → 90 | 36.94 |
| 2026-09-18 | RBC Capital | Target Lowered | 81 → 70 | 40.28 |
| 2026-09-18 | Wedbush | Target Lowered | 71 → 55 | 57.35 |
| 2026-09-18 | Needham | Target Lowered | 78 → 60 | 57.35 |
| 2026-09-18 | Robert W. Baird | Target Lowered | 97 → 90 | 57.35 |
| 2026-09-18 | Wells Fargo | Target Lowered | 69 → 64 | 57.35 |
| 2026-09-18 | Deutsche Bank | Update | — → 46 | 57.35 |
| 2026-08-10 | H.C. Wainwright | Update | — → 74 | 63.36 |
| 2026-08-07 | RBC Capital | Target Lowered | 82 → 81 | 63.55 |
| 2026-05-10 | Wells Fargo | Target Raised | 68 → 69 | 56.44 |
| 2026-05-08 | Needham | Target Lowered | 80 → 78 | 56.545 |
| 2026-03-10 | Deutsche Bank | Target Raised | 56 → 90 | 60.61 |
| 2026-03-09 | RBC Capital | Target Raised | 59 → 80 | 62.76 |
| 2026-03-09 | Jefferies | Target Raised | — → 100 | 62.76 |
| 2026-03-09 | Guggenheim | Target Raised | — → 90 | 62.76 |
| 2026-03-09 | Morgan Stanley | Target Raised | — → 97 | 62.76 |
| 2026-03-09 | Robert W. Baird | Target Raised | — → 97 | 62.76 |
| 2026-03-09 | Stifel Nicolaus | Target Raised | — → 89 | 61.58 |
| 2026-03-09 | Jefferies | Update | — → 65 | 61.56 |
